# Application of (chemo)proteomic methods to map cancer biochemical pathways

> **NIH NIH R50** · SCRIPPS RESEARCH INSTITUTE, THE · 2020 · $168,678

## Abstract

ABSTRACT
The Cravatt lab has a long history of developing and applying advanced chemical proteomic and metabolomic
techniques to dissect and target biochemical pathways in cancer. We have continuously been funded by the
NCI for over 15 years, and currently have programs funded through 2020. The foundation of this research is
cutting-edge mass spectrometry (MS)-based techniques that are continually developed and applied to
elucidate critical protein modulators of cancer pathogenicity. Identification of essential mediators of cancer
growth will enable development of potent and selective novel cancer therapeutics. Our cancer-related
research can be broken up into three main programs: 1) development of innovative chemical proteomic
methods for mapping oncogenic pathways and drugs that target these pathways in cancer (CA087660); 2)
identification of deregulated metabolic pathways in cancer and proteins within these pathways that may
represent novel targets for cancer treatment (CA132630); and 3) application of our activity-based proteomic
methods to identify serine hydrolases responsible for regulation of the palmitoylation state of oncogenic N-Ras
in cancer (CA193994). These research programs are dependent on a variety of proteomic and metabolomic
MS-based methods for their successful completion. As the only senior staff member in the Cravatt lab, I play
an essential role in the planning and execution of all MS based projects, either by directly performing the highly
specialized techniques, or by training lab members and/or collaborators. We also have a number of
collaborations that rely heavily on MS instruments. I am responsible for managing these collaborations and
either performing the experiments and communicating the results, or managing the people that perform the
experiments. I also play an indispensible role in troubleshooting and instrument maintenance, ensuring that all
of the Cravatt lab's MS-instruments are performing at optimal levels, which is essential to achievement of the
goals for all of our NCI-funded research programs.

## Key facts

- **NIH application ID:** 10001009
- **Project number:** 5R50CA211526-05
- **Recipient organization:** SCRIPPS RESEARCH INSTITUTE, THE
- **Principal Investigator:** Melissa Dix Simon
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $168,678
- **Award type:** 5
- **Project period:** 2016-09-15 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10001009

## Citation

> US National Institutes of Health, RePORTER application 10001009, Application of (chemo)proteomic methods to map cancer biochemical pathways (5R50CA211526-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10001009. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*